Research programme: recombinant human biglycan - Tivorsan

Drug Profile

Research programme: recombinant human biglycan - Tivorsan

Alternative Names: Biglycan; rh-BGN; TVN-102

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Brown University
  • Developer Tivorsan Pharmaceuticals
  • Class Proteoglycans
  • Mechanism of Action Utrophin activators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Duchenne muscular dystrophy
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Amyotrophic lateral sclerosis; Muscular dystrophies
  • No development reported Duchenne muscular dystrophy

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Duchenne muscular dystrophy in USA (Parenteral, Injection)
  • 15 Aug 2016 Recombinant human biglycan - Tivorsan receives Orphan Drug status for Duchenne muscular dystrophy in USA
  • 15 Aug 2016 Tivorsan Pharmaceuticals announces intention to submit IND application for phase I trials of recombinant human biglycan, TVN 102
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top